Patenting Polymorphic Forms at the European Patent Office



Similar documents
dependent independent claims

Patentability of inventions in the field of food industry: search and examination practice at the EPO


Introduction to X-Ray Powder Diffraction Data Analysis

Part II. Application not searched. Application not searched due to the presence of certain subject matter

New Portable X-Ray Diffraction/X-Ray Fluorescence Instrument (XRD/XRF)

Comments on Draft Guidelines. for Examination of. Patent Applications in the Field of Pharmaceuticals. before the Indian Patent Office (IPO)

TEPZZ 597Z9ZA_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION

Patents for software?

X-Ray Diffraction HOW IT WORKS WHAT IT CAN AND WHAT IT CANNOT TELL US. Hanno zur Loye

Date of decision 15 July Case number T 0208/ Application number EP G06F15/20

Al 2 O 3, Its Different Molecular Structures, Atomic Layer Deposition, and Dielectrics

ANALYSIS OF ASPIRIN INFRARED (IR) SPECTROSCOPY AND MELTING POINT DETERMINATION

IUCLID 5 COMPOSITION AND ANALYSIS GUIDANCE DOCUMENT: IRON ORES, AGGLOMERATES [EINECS NUMBER , CAS NUMBER ] IRON ORE PELLETS

European Patenting Practice... with a view on USPTO Differences. Michael Schneider European Patent Attorney Eversheds, Munich

Quantifying Amorphous Phases. Kern, A., Madsen, I.C. and Scarlett, N.V.Y.

European Patent Office / State Intellectual Property Office of the People s Republic of China

Defining the Scope of Search and Examination

X-ray Powder Diffraction Pattern Indexing for Pharmaceutical Applications

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

From lowest energy to highest energy, which of the following correctly orders the different categories of electromagnetic radiation?

-FREE FATTY ACID POWDER FORMS

PATENTS ACT IN THE MATTER OF Application No. GB in the name of Pintos Global Services Ltd DECISION. Introduction

ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.

LIFE SCIENCE I TECHNICAL BULLETIN ISSUE N 11 /JULY 2008

Unit title: Chemical Laboratory Techniques

Decision of Technical Board of Appeal dated 21 April 2004 T 258/

Patents for software?

Using the PDF for material identification using elemental data. from XRF and SEM EDS.

Bruker AXS. D2 PHASER Diffraction Solutions XRD. think forward

PATENTS. Pharmaceutical Product Patenting Strategies

Suggested solutions for Chapter 3

X-ray Diffraction and EBSD

PURIFICATION TECHNIQUES

Annex I Common Requirements for All Types of Documents

DETECTION OF COATINGS ON PAPER USING INFRA RED SPECTROSCOPY

Back to Basics Fundamentals of Polymer Analysis

Computer-Implemented Inventions EPO

SPECTROSCOPIC STUDIES ON DEGRADATION OF POLY N,N'-METHYLENE BISACRYLAMIDE

Crystal Structure of High Temperature Superconductors. Marie Nelson East Orange Campus High School NJIT Professor: Trevor Tyson

Production of X-rays. Radiation Safety Training for Analytical X-Ray Devices Module 9

J.A.Kemp & Co. London. Munich. Oxford

GLOSSARY OF PATENT TERMINOLOGY

The unbearable conundrum of patenting software

Application Note AN4

PATENT COOPERATION TREATY (PCT)

Features of the formation of hydrogen bonds in solutions of polysaccharides during their use in various industrial processes. V.Mank a, O.

The Fundamentals of Infrared Spectroscopy. Joe Van Gompel, PhD

Raman spectroscopy Lecture

AMBERLITE IRP64 Pharmaceutical Grade Cation Exchange Resin (Polacrilex Resin)

Proton Nuclear Magnetic Resonance Spectroscopy

Current Staff Course Unit/ Length. Basic Outline/ Structure. Unit Objectives/ Big Ideas. Properties of Waves A simple wave has a PH: Sound and Light

Phase Characterization of TiO 2 Powder by XRD and TEM

Crystal Structure Determination I

Guidance for Industry

CERTIFICATE OF ANALYSIS Methyl 4-Hydroxybenzoate

INVENTIONS, PATENTS AND LICENSING POLICY

EUDRAGIT E 100, EUDRAGIT E PO and

Generation of X-Rays (prepared by James R. Connolly, for EPS , Introduction to X-Ray Powder Diffraction, Spring 2005)

Scuola di dottorato in Scienze molecolari Information literacy in chemistry Patents

EXPERIMENT 1 (Organic Chemistry I)

CHEM 51LB: EXPERIMENT 5 SPECTROSCOPIC METHODS: INFRARED AND NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY

Introduction to Powder X-Ray Diffraction History Basic Principles

Symmetric Stretch: allows molecule to move through space

Growth and Characterisation of Gudolinium doped Sulphamic acid Single Crystal

How To Teach A Patent Course On Life Sciences

Patent Cooperation Treaty (PCT)

PCV Project: Excitons in Molecular Spectroscopy

CHE334 Identification of an Unknown Compound By NMR/IR/MS

GUIDELINES FOR PATENT EXAMINATION IN THE INTELLECTUAL PROPERTY CORPORATION OF MALAYSIA

BIOPATENTS IN CHINA. Christopher Shaowei Heather Lin. April 4, 2014, Budapest, Hungary 2014/4/4 NTD IP ATTORNEYS

WEEKLY COURSE SCHEDULE : PRIMARY EDUCATION

Melting Range 1 Experiment 2

Contents. Contributors. 1 Quality control and regulation 1 C.J. MOORES

Supporting Information

Norway Advokatfirmaet Grette

2. Deposition process

NEEM and HOODIA. Two European Patent Applications involving Traditional Knowledge

IN THE MATTER OF International Application No PCT/GB 2003/ in the name of PENIFE INTERNATIONAL LIMITED

Burcu Saner, Firuze Okyay, Fatma Dinç, Neylan Görgülü, Selmiye Alkan Gürsel and Yuda Yürüm*

Our patent and trade mark attorneys are here to help you protect and profit from your ideas, making sure they re working every bit as hard as you do.

Heterogeneous Homogenous. Mixtures; Solutions. Phases of matter: Solid. Phases of Matter: Liquid. Phases of Matter: Gas. Solid, Liquid, Gas

The European Patent Register. An introductory guide

Infrared Spectroscopy: Theory

Phase Diagrams & Thermodynamics

Absorption by atmospheric gases in the IR, visible and UV spectral regions.

Effect of surface area, pore volume and particle size of P25 titania on the phase transformation of anatase to rutile

IP Litigation in Europe and in Germany

Matter, Materials, Crystal Structure and Bonding. Chris J. Pickard

Chapter 16: Tests for ions and gases

INFRARED SPECTROSCOPY (IR)

MEDICAL/PHARMACEUTICAL INVENTIONS. A comparative study Europe China

Ultraviolet Spectroscopy

The identification of tablets and capsules containing barbiturates by MATR infrared spectroscopy

6. We believe that the Guidance does not accord with TRIPs. Any administrative or judicial interpretation of the provisions of any statute,

Bridging the analytical gap

NIR Chemical Imaging as a Process Analytical Tool

INTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES

Group Theory and Chemistry

Audit Report and Requirements of Mantid Software from the Molecular Spectroscopy Group (2013)

Transcription:

Patenting Polymorphic Forms at the S. Fanni and J.-D. Moriggi Pure & Applied Organic Chemistry, Munich 05/11/2014 Patentability Requirements Clarity (Article 84 EPC) & further requirements to the claims Disclosure (Article 83 EPC) Novelty (Article 54 EPC) Inventive Step (Article 56 EPC) Unity of invention (Article 82 EPC) 2 1

Clarity, Support, Conciseness (Article 84 EPC) The claims shall define the matter for which protection is sought. They shall be clear and concise and be supported by the description. 3 Clarity: definition of polymorphs SUITABLE Physicochemical parameters single crystal or powder XRD IR or Raman spectroscopy solid state 13 C-NMR thermal methods: TGA, DTA, DSC Product by process NOT SUITABLE "Crystalline form δ of compound X" 4 2

Clarity: practical points for using parameters The parameters shall be reliable The measurement conditions shall be included in the claims (there are only few exceptions to this rule) Unusual parameters or the use of a non-accessible apparatus for measurement are objectionable for lack of clarity, as no comparison can be made with the prior art (guidelines, F-IV, 4.11 and 4.18) 5 Clarity: sample claims of granted patents Crystalline form of compound X, characterised by main peaks in its powder X-ray diffraction pattern obtained using copper K-alpha 1 radiation at 9.0, 14.2, 23.9 and 27.1 ± 0.2 degree 2-theta. Polymorph B of compound X, characterised by an infrared absorption spectrum in potassium bromide having absorption bands at 3412, 1713, 1250, 1238, 1150, 1091, 751, 744, 704, and 693 reciprocal centimetres. 6 3

Further requirements to the claims Multiple independent claims directed to the same product do not comply with Rule 43(2) EPC References to figures in the drawings do not comply with Rule 43(6) EPC "except where absolutely necessary" According to Rule 49(9) EPC, the claims shall not contain drawings 7 Patentability Requirements Clarity (Article 84 EPC) & further requirements to the claims Disclosure (Article 83 EPC) Novelty (Article 54 EPC) Inventive Step (Article 56 EPC) Unity of invention (Article 82 EPC) 8 4

Sufficiency of disclosure (Article 83 EPC) The European patent application must disclose the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art. 9 Disclosure and solid state inventions Lack of sufficient disclosure may arise if: the application does not clearly describe the method used to determine the parameters of the claimed solid state form the preparation process in the application is identical to those of the prior art, but a different solid state form is allegedly obtained all preparation processes described involve seeding, but preparation of the seed crystals is not described (T 1066/03) (guidelines 2013, F-III.3-4) 10 5

Patentability Requirements Clarity (Article 84 EPC) & further requirements to the claims Disclosure (Article 83 EPC) Novelty (Article 54 EPC) Inventive Step (Article 56 EPC) Unity of invention (Article 82 EPC) 11 Novelty (Article 54 EPC) An invention shall be considered to be new if it does not form part of the state of the art. The state of the art shall be held to comprise everything made available to the public by means of a written or oral description, by use, or in any other way, before the date of filing of the European patent application. 12 6

Novelty: parameters and decision T 296/87 Polymorphic forms are usually defined in a claim by parameters A chemical substance is considered novel if it differs from a known substance in a reliable parameter (decision T 296/87) 13 Novelty: enabling disclosure To challenge novelty a prior art document must be enabling, i.e. the information in the document together with the common general knowledge must enable the skilled person to prepare the compound in question A document disclosing the parameters of a crystal form but neither its source nor its preparation is not enabling and cannot challenge novelty (T 605/02) 14 7

Novelty: implicit disclosure and parameters The prior art is enabling and discloses the same compound as the claimed crystal form also in crystalline form but with no or different parametric definitions Guidelines, G-VI.6. [...] It may happen that in the relevant prior art a different parameter, or no parameter at all, is mentioned. If the known and the claimed products are identical in all other respects then in the first place an objection of lack of novelty arises [...] (decision T 1753/06) 15 Patentability Requirements Clarity (Article 84 EPC) & further requirements to the claims Disclosure (Article 83 EPC) Novelty (Article 54 EPC) Inventive Step (Article 56 EPC) Unity of invention (Article 82 EPC) 16 8

Inventive step (Article 56 EPC) An invention shall be considered as involving an inventive step if, having regard to the state of the art, it is not obvious to a person skilled in the art. At the EPO, inventive step is assessed according to the problem-andsolution approach, based on the principle that an invention is the solution of a technical problem 17 Inventive step: problem-and-solution approach 1. The closest prior art is determined 2. Starting from the closest prior art, the objective technical problem to be solved is established 3. An assessment is made of whether, in the light of the prior art, it would have been obvious to solve the objective technical problem in the way claimed 18 9

Inventive step: problem-and-solution approach Closest prior art A document disclosing the same compound in (different) crystalline, non-crystalline or unspecified form Objective technical problem 1. Provision of an alternative form of a known compound to achieve the same technical effect as the prior art 2. Provision of a further form of a known compound with a different (unexpected) property or effect 19 Inventive step: technical problem 1 Problem to be solved: same technical effect as the closest prior art form (e.g. same pharmaceutical activity) In the pharmaceutical industry the skilled person would routinely investigate an API for polymorphs If such routine leads to an alternative crystal form, i.e. another polymorph, the mere provision of this alternative would likely be considered as an obvious solution of the technical problem Inventive step would then be denied 20 10

Inventive step: technical problem 2 Problem to be solved: different property or effect than the closest prior art (e.g. improved bioavailability, lower hygroscopicity, etc.) If the skilled person has no reasons to expect said different property or effect, it would not be obvious to provide the claimed crystalline form in order to solve the technical problem Inventive step would then be acknowledged The presence of the different property or effect must be shown visà-vis the compound of the closest prior art 21 Inventive step: example (T 777/08) Claimed: a crystalline form of compound X Closest prior art: compound X in amorphous form Test showing a better filterability and drying characteristics Objective technical problem: the provision of an alternative form with improved filterability and drying characteristics Additional prior art cited (common knowledge): in pharmaceutical industry crystalline products are generally easier to isolate, purify, dry, etc. Decision: in the absence of any unexpected property the mere provision of a crystalline form of a known API cannot be regarded as inventive 22 11

Patentability Requirements Clarity (Article 84 EPC) & further requirements to the claims Disclosure (Article 83 EPC) Novelty (Article 54 EPC) Inventive Step (Article 56 EPC) Unity of invention (Article 82 EPC) 23 Unity of invention (Article 82 EPC) The European patent application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept....the requirement of unity of invention... shall be fulfilled only where there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those features which define a contribution which each of the claimed inventions considered as a whole makes over the prior art. (Rule 44(1) EPC) 24 12

Unity of invention: example Claimed: crystalline forms β, γ and δ of compound X Closest prior art: crystalline form α of compound X Each of the polymorphic forms β, γ and δ differs from the known form α through its specific crystalline form. However, the specific crystalline form of each polymorph is unique to it and not shared by any other polymorph The application relates to three separate inventions, i.e. 1) polymorph β 2) polymorph γ 3) polymorph δ 25 Köszönöm a figyelmet! Van kérdés? Dr Stefano FANNI Examiner, Directorate 1452 Pure and Applied Chemistry Munich, Germany Tel. +49 (0) 89 2399 8712 sfanni@epo.org www.epo.org Dr Jean-Dominique MORIGGI Examiner, Directorate 1462 Pure and Applied Chemistry Munich, Germany Tel. +49 (0) 89 2399 2692 jmoriggi@epo.org www.epo.org 26 13